НМГ не повышает шансов на вынашивание при необъяснимом повторном раннем выкидыше

[Dr.Vad]

НМГ не улучшает прогноз при повторных невынашиваниях у женщин и с тромбофилией - настало время перестать искать генетические тромбофилии у женщин с повторными невынашиваниями:

326 conceived and were randomly assigned (164 to LMWH and 162 to standard care). 116 (72%) of 162 women with primary outcome data in the LMWH group and 112 (71%) of 158 in the standard care group had livebirths (adjusted odds ratio 1·08, 95% CI 0·65 to 1·78; absolute risk difference, 0·7%, 95% CI -9·2% to 10·6%). 39 (24%) of 164 women in the LMWH group and 37 (23%) of 162 women in the standard care group reported adverse events.

Interpretation:
We do not advise use of LMWH in women with recurrent pregnancy loss and inherited thrombophilia, and we advise against screening for inherited thrombophilia in women with recurrent pregnancy loss.
---
Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.

[Ссылки доступны только зарегистрированным пользователям ]